Contributions
Abstract: PB2121
Type: Publication Only
Background
In 2014 the definition of smoldering multiple myeloma (sMM) was updated by the International Myeloma Working Group (IMWG). Thus, at present, the detection of SLIM CRAB can be considered for treatment need. In addition, several clinical and biological predictors of progression to symptomatic MM can be used to discriminate sMM patients on the basis of their different degree of risk of progression. Beside to the validated criteria included in Mayo Clinic or Spanish models, several other potential biomarkers have been each time proposed. We previously demonstrated that LIGHT/TNFSF14, a TNF superfamily member, is over-expressed on CD14+ monocytes, CD8+ T-cells and neutrophils of patients with MM lytic bone disease.
Aims
Given lytic bone disease as the most frequent MM-defining event in symptomatic MM patients, here we aimed to test LIGHT as potential biomarker for progression of sMM to symptomatic MM.
Methods
PB samples were obtained from 58 patients (30 M/28 F, 63 ± 10 years) newly diagnosed as having symptomatic MM with related-bone disease, 60 with sMM (36/24, M/F, 54 ± 20 years) and 50 healthy controls. Patients and controls were age and sex matched. Patients were diagnosed as having symptomatic MM or sMM based on IMWG criteria. By means of multiparameter flow cytometry (MFC), we evaluated LIGHT expression on circulating CD14+-monocytes, CD16+-neutrophils, CD4+- and CD8+-T cells. The results were compared to those obtained in healthy controls.
Results
The levels of LIGHT measured on CD14+ monocytes of symptomatic MM, sMM patients, compared to those of healthy controls gave the following results: 47.1% ± 9.5% (range 30-90%), 14.75% ± 20% (range 0-88%) vs 2.1 %± 1.2 (range 0-4%), p<0.01. In addition, we found that in sMM patients, LIGHT levels positively correlated with high involved/uninvolved serum free light chain (FLC) ratio r= 0.613 p<0.001.
Conclusion
Several clinical and biological biomarkers have recently been proposed to stratify sMM patients on their risk of progression to symptomatic disease. Based on the positive correlation between LIGHT expression levels on circulating monocytes, and involved/uninvolved serum FLC ratio, we could argue that LIGHT may be further assessed as a potential biological precursor of lytic bone-disease development in sMM patients. Reliable clinical and biological biomarkers for risk stratification of sMM can allow to plan optimized follow-up as well as to identify further subgroups of patients, who could benefit from an early treatment. The high levels of LIGHT expressed by circulating monocytes and their correlation with FLC ratio, suggest a possible role of this cytokine as biological predictor of sMM progression to symptomatic MM.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research
Abstract: PB2121
Type: Publication Only
Background
In 2014 the definition of smoldering multiple myeloma (sMM) was updated by the International Myeloma Working Group (IMWG). Thus, at present, the detection of SLIM CRAB can be considered for treatment need. In addition, several clinical and biological predictors of progression to symptomatic MM can be used to discriminate sMM patients on the basis of their different degree of risk of progression. Beside to the validated criteria included in Mayo Clinic or Spanish models, several other potential biomarkers have been each time proposed. We previously demonstrated that LIGHT/TNFSF14, a TNF superfamily member, is over-expressed on CD14+ monocytes, CD8+ T-cells and neutrophils of patients with MM lytic bone disease.
Aims
Given lytic bone disease as the most frequent MM-defining event in symptomatic MM patients, here we aimed to test LIGHT as potential biomarker for progression of sMM to symptomatic MM.
Methods
PB samples were obtained from 58 patients (30 M/28 F, 63 ± 10 years) newly diagnosed as having symptomatic MM with related-bone disease, 60 with sMM (36/24, M/F, 54 ± 20 years) and 50 healthy controls. Patients and controls were age and sex matched. Patients were diagnosed as having symptomatic MM or sMM based on IMWG criteria. By means of multiparameter flow cytometry (MFC), we evaluated LIGHT expression on circulating CD14+-monocytes, CD16+-neutrophils, CD4+- and CD8+-T cells. The results were compared to those obtained in healthy controls.
Results
The levels of LIGHT measured on CD14+ monocytes of symptomatic MM, sMM patients, compared to those of healthy controls gave the following results: 47.1% ± 9.5% (range 30-90%), 14.75% ± 20% (range 0-88%) vs 2.1 %± 1.2 (range 0-4%), p<0.01. In addition, we found that in sMM patients, LIGHT levels positively correlated with high involved/uninvolved serum free light chain (FLC) ratio r= 0.613 p<0.001.
Conclusion
Several clinical and biological biomarkers have recently been proposed to stratify sMM patients on their risk of progression to symptomatic disease. Based on the positive correlation between LIGHT expression levels on circulating monocytes, and involved/uninvolved serum FLC ratio, we could argue that LIGHT may be further assessed as a potential biological precursor of lytic bone-disease development in sMM patients. Reliable clinical and biological biomarkers for risk stratification of sMM can allow to plan optimized follow-up as well as to identify further subgroups of patients, who could benefit from an early treatment. The high levels of LIGHT expressed by circulating monocytes and their correlation with FLC ratio, suggest a possible role of this cytokine as biological predictor of sMM progression to symptomatic MM.
Session topic: 13. Myeloma and other monoclonal gammopathies – Biology & Translational Research